0
0
India’s fight against dengue could soon reach a major milestone as the country’s first indigenous dengue vaccine candidate moves closer to completing enrolment for its pivotal Phase 3 clinical trial. The Indian Council of Medical Research (ICMR) and Panacea Biotec are on track to finish enrolling participants by October 2025, marking a crucial step in the development of a homegrown solution to one of India’s most persistent public health threats.
Over 70% of the targeted 10,335 adult volunteers have already been enrolled across 20 leading medical centres in cities including Chennai, Pune, Hyderabad, Bengaluru, New Delhi, and Kolkata. The trial, launched on August 14, 2024, is a multi-centre, double-blind, randomised, placebo-controlled study designed to rigorously assess the vaccine’s efficacy, safety, and long-term immune response.
Once enrolment is complete, each participant will be followed for two years, with this critical observation period expected to conclude by the end of 2027. Only after a comprehensive analysis of the trial’s safety and efficacy data will Panacea Biotec and ICMR submit their findings to the Central Drugs Standard Control Organization (CDSCO) for regulatory review and potential market authorization.
So far, official sources report that the enrolment process is progressing smoothly, with no safety concerns observed among participants. The vaccine candidate’s single-dose regimen is seen as a major advantage, potentially making mass immunisation campaigns more feasible and cost-effective, especially in dengue-endemic regions.
Earlier Phase 1 and 2 trials conducted in India demonstrated a strong safety profile and robust immune response, earning regulatory clearance to proceed to this final phase. If the vaccine proves effective and safe in the ongoing trial, it could address key challenges faced by existing international dengue vaccines, such as the need for multiple doses and limited efficacy across different virus strains.
India faces seasonal dengue outbreaks every year, resulting in thousands of hospitalisations and placing significant strain on the healthcare system. The World Health Organization estimates that around 390 million dengue infections occur globally each year, with India bearing a substantial portion of the burden. Currently, there is no specific antiviral treatment for dengue, making prevention through vaccines and vector control essential.
If successful, this vaccine could become a game-changer not only for India but also for other countries grappling with high dengue incidence, particularly in lower-income regions.
Disclaimer: The dengue vaccine candidate is still under clinical investigation. Final approval and public availability will depend on the successful completion of Phase 3 trials, comprehensive safety and efficacy analysis, and regulatory review. No conclusions about the vaccine’s effectiveness or safety should be drawn until these processes are complete.
